PIII Company Profile and Key Details

PIII has shown weak momentum, losing -1.69% over the past week and -67.71% over the past quarter, though year-to-date performance is down -16.91%. Short-term trend indicators are bullishly aligned (SMA20 7.22%, SMA50 -22.79%, SMA200 -64.5%). The stock’s 14-day RSI is 44.94 (neutral), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.35% below its high and over 46.05% above its low. Average 10-day trading volume of 9.75 thousand shares is below the 3-month average of 35.92 thousand, indicating normal recent market interest.

P3 Health Partners Inc. generated EPS of -$43.00 over the past year. Five-year average earnings growth is -8.0%. The latest quarter delivered EPS of -$0.63. The next quarter is forecast at -$8.06. Next year's EPS is expected at $55.09. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 98.58% upside. The low target suggests -57.45% downside. The mean target is $9.50. This offers 34.75% upside. P3 Health Partners Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by -66.67%. The prior quarter beat by -107.63%. Over the last six quarters, Apple has recorded several small beats. These include 25.6% in May 15, 2025.

P3 Health Partners Inc. has 3.33 million shares outstanding. The public float is 1.39 million shares, elevated short interest at 1.51% of float. This equals 38.30 thousand shares. The short ratio is 1.21 days. Institutional investors hold 16.97% of the float. Insiders own 56.91%. LEAVITT LEGACY, LLC holds 7.97 million shares, Balkin Michael has 7.55 million shares and Chicago Pacific Founders UGP III, LLC has 1.43 million shares. Over the past six months, insider transactions show net selling. They sold 29.88 thousand shares across 1 transactions.

P3 Health Partners Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.02. This means the shares are trading below this model’s fair value.

P3 Health Partners Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.02 and a price-to-book ratio of 0.33 suggesting the stock is closer to book value. The P/FCF stands at -0.18, also above market averages.

The stock is currently mid-range between its 52-week high and low $1.52 and $16.89. With a market capitalization of about $23.10 million, P3 Health Partners Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.62). Key stats such as the average daily volume over the past year has been around 37.00 thousand shares, volume is running light vs its 52-week average. Headquartered in Henderson, NV, P3 Health Partners Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Aric Coffman, the company employs approximately 320 people and listed since April 06, 2021. P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States.

Our AI price prediction model suggests that P3 Health Partners Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.15%, with price expected at $5.70 by October 09, 2026, within a range of $5.22 to $6.13 3-Month Outlook: Projected fall of -90.92%, reaching $0.64 by December 24, 2026, with a range of $0.20 to $1.04. 1-Year Outlook: Projected gain of 288.65%, with price at $27.40 by September 24, 2027, within a range of $25.47 to $33.89.

P3 Health Partners Inc. (NASDAQ:PIII) shares are down -16.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows P3 Health Partners Inc. trading at a premium to the broader market with a P/E of -0.21. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $9.09, suggesting 28.94% upside. Our AI forecast model points to short-term weakness (-19.15% over two weeks), a medium-term fall (-90.92% over three months), and a longer-term gain (288.65% over one year), with expected trading ranges indicating moderate volatility.